Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 17-35

  Bonekamp, Susanne ^a   Kamel, Ihab ^a   Solga, Steven ^a   Clark, Jeanne ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis; Imaging; Radiology

Indexed keywords

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; DISEASE SEVERITY; ECHOGRAPHY; ELASTOGRAPHY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW;

DIAGNOSTIC IMAGING; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 56949092389     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.10.016     Document Type: Article

References (194)

1. Poynard T., McHutchison J., Davis G.L., Esteban-Mur R., Goodman Z., Bedossa P., et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32 (2000) 1131-1137 Nov
2. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132 (2000) 517-524
3. Dixon J.B., Bhathal P.S., Hughes N.R., and O'Brien P.E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39 (2004) 1647-1654
4. Farci P., Roskams T., Chessa L., Peddis G., Mazzoleni A.P., Scioscia R., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126 (2004) 1740-1749
5. Fowell A.J., and Iredale J.P. Emerging therapies for liver fibrosis. Dig Dis 24 (2006) 174-183
6. Friedman S.L., and Bansal M.B. Reversal of hepatic fibrosis - fact or fantasy?. Hepatology 43 (2006) S82-S88
7. Goldin R.D., Goldin J.G., Burt A.D., Dhillon P.A., Hubscher S., Wyatt J., et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 25 (1996) 649-654
8. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
9. Fontana R.J., and Lok A.S. Non-invasive monitoring of patients with chronic hepatitis C. Hepatology 36 (2002) S57-S64
10. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005) 343-350
11. Castera L., Foucher J., Bertet J., Couzigou P., and de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 43 (2006) 373-374
12. Guha I.N., Parkes J., Roderick P.R., Harris S., and Rosenberg W.M. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 55 (2006) 1650-1660
13. Parkes J., Guha I.N., Roderick P., and Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 44 (2006) 462-474
14. Halfon P., Bourliere M., Penaranda G., and Cacoub P. Non-invasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy. Presse Med 36 (2007) 457-466
15. Morra R., Munteanu M., Imbert-Bismut F., Messous D., Ratziu V., and Poynard T. FibroMAX: Towards a new universal biomarker of liver disease?. Expert Rev Mol Diagn 7 (2007) 481-490
16. Shaheen A.A., Wan A.F., and Myers R.P. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 102 (2007) 2589-2600
17. Stauber R.E., and Lackner C. Non-invasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 13 (2007) 4287-4294
18. Needleman L., Kurtz A.B., Rifkin M.D., Cooper H.S., Pasto M.E., and Goldberg B.B. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. AJR Am J Roentgenol 146 (1986) 1011-1015
19. Saverymuttu S.H., Joseph A.E., and Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292 (1986) 13-15
20. Tchelepi H., Ralls P.W., Radin R., and Grant E. Sonography of diffuse liver disease. J Ultrasound Med 21 (2002) 1023-1032
21. Oberti F., Valsesia E., Pilette C., Rousselet M.C., Bedossa P., Aube C., et al. Non-invasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 113 (1997) 1609-1616
22. Aube C., Oberti F., Korali N., Namour M.A., Loisel D., Tanguy J.Y., et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 30 (1999) 472-478
23. Shen L., Li J.Q., Zeng M.D., Lu L.G., Fan S.T., and Bao H. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 12 (2006) 1292-1295
24. Colli A., Fraquelli M., Andreoletti M., Marino B., Zuccoli E., and Conte D. Severe liver fibrosis or cirrhosis: Accuracy of US for detection - analysis of 300 cases. Radiology 227 (2003) 89-94
25. Colli A., Colucci A., Paggi S., Fraquelli M., Massironi S., Andreoletti M., et al. Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol 11 (2005) 7318-7322
26. Zheng R.Q., Wang Q.H., Lu M.D., Xie S.B., Ren J., Su Z.Z., et al. Liver fibrosis in chronic viral hepatitis: an ultrasonographic study. World J Gastroenterol 9 (2003) 2484-2489
27. Colli A., Cocciolo M., Mumoli N., Cattalini N., Fraquelli M., and Conte D. Hepatic artery resistance in alcoholic liver disease. Hepatology 28 (1998) 1182-1186
28. Bernatik T., Strobel D., Hahn E.G., and Becker D. Doppler measurements: a surrogate marker of liver fibrosis?. Eur J Gastroenterol Hepatol 14 (2002) 383-387 Apr
29. Kurz A.K., and Blum H.E. Duplexsonography of the liver: state-of-the-art and perspectives. Dtsch Med Wochenschr 131 (2006) 1035-1039
30. Bolognesi M., Sacerdoti D., Mescoli C., Bombonato G., Cillo U., Merenda R., et al. Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: analysis of explanted liver weight, degree of fibrosis and splanchnic doppler parameters. Scand J Gastroenterol 42 (2007) 256-262
31. Arda K., Ofelli M., Calikoglu U., Olcer T., and Cumhur T. Hepatic vein doppler waveform changes in early stage (child-pugh A) chronic parenchymal liver disease. J Clin Ultrasound 25 (1997) 15-19
32. Dietrich C.F., Lee J.H., Gottschalk R., Herrmann G., Sarrazin C., Caspary W.F., et al. Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. AJR Am J Roentgenol 171 (1998) 437-443
33. Haktanir A., Cihan B.S., Celenk C., and Cihan S. Value of doppler sonography in assessing the progression of chronic viral hepatitis and in the diagnosis and grading of cirrhosis. J Ultrasound Med 24 (2005) 311-321
34. von Herbay A., Frieling T., and Haussinger D. Association between duplex doppler sonographic flow pattern in right hepatic vein and various liver diseases. J Clin Ultrasound 29 (2001) 25-30
35. Oguzkurt L., Yildirim T., Torun D., Tercan F., Kizilkilic O., and Niron E.A. Hepatic vein doppler waveform in patients with diffuse fatty infiltration of the liver. Eur J Radiol 54 (2005) 253-257
36. Hirche T.O., Ignee A., Hirche H., Schneider A., and Dietrich C.F. Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver Int 27 (2007) 748-757
37. Barbaro B., Manfredi R., Bombardieri G., Vecchio F.M., Palazzoni G., Mancini A.P., et al. Correlation of MRI liver volume and doppler sonographic portal hemodynamics with histologic findings in patients with chronic hepatitis C. J Clin Ultrasound 28 (2000) 461-468
38. Schneider A.R., Teuber G., Kriener S., and Caspary W.F. Non-invasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection. Liver Int 25 (2005) 1150-1155
39. Cosar S., Oktar S.O., Cosar B., Yucel C., and Ozdemir H. Doppler and gray-scale ultrasound evaluation of morphological and hemodynamic changes in liver vascualture in alcoholic patients. Eur J Radiol 54 (2005) 393-399
40. Blomley M.J., Lim A.K., Harvey C.J., Patel N., Eckersley R.J., Basilico R., et al. Liver microbubble transit time compared with histology and child-pugh score in diffuse liver disease: A cross sectional study. Gut 52 (2003) 1188-1193
41. Lim A.K., Taylor-Robinson S.D., Patel N., Eckersley R.J., Goldin R.D., Hamilton G., et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 54 (2005) 128-133
42. Lim A.K., Patel N., Eckersley R.J., Goldin R.D., Thomas H.C., Cosgrove D.O., et al. Hepatic vein transit time of SonoVue: a comparative study with levovist. Radiology 240 (2006) 130-135
43. Klibanov A.L. Ultrasound molecular imaging with targeted microbubble contrast agents. J Nucl Cardiol 14 (2007) 876-884
44. Albrecht T., Blomley M.J., Cosgrove D.O., Taylor-Robinson S.D., Jayaram V., Eckersley R., et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 353 (1999) 1579-1583
45. Maruyama H., Matsutani S., Okugawa H., Kobayashi S., Yoshizumi H., Ebara M., et al. Microbubble disappearance-time is the appropriate timing for liver-specific imaging after injection of levovist. Ultrasound Med Biol 32 (2006) 1809-1815
46. Kaneko T., Teshigawara O., Sugimoto H., Hirota M., Inoue S., Takeda S., et al. Signal intensity of the liver parenchyma in microbubble contrast agent in the late liver phase reflects advanced fibrosis of the liver. Liver Int 25 (2005) 288-293
47. Iijima H., Moriyasu F., Tsuchiya K., Suzuki S., Yoshida M., Shimizu M., et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 37 (2007) 722-730
48. Dickinson R.J., and Hill C.R. Measurement of soft tissue motion using correlation between A-scans. Ultrasound Med Biol 8 (1982) 263-271
49. Krouskop T.A., Dougherty D.R., and Vinson F.S. A pulsed doppler ultrasonic system for making non-invasive measurements of the mechanical properties of soft tissue. J Rehabil Res Dev 24 (1987) 1-8
50. Lerner R.M., Huang S.R., and Parker K.J. "Sonoelasticity" images derived from ultrasound signals in mechanically vibrated tissues. Ultrasound Med Biol 16 (1990) 231-239
51. Parker K.J., Huang S.R., Musulin R.A., and Lerner R.M. Tissue response to mechanical vibrations for "sonoelasticity imaging. Ultrasound Med Biol 16 (1990) 241-246
52. Ophir J., Cespedes I., Ponnekanti H., Yazdi Y., and Li X. Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Imaging 13 (1991) 111-134
53. Sanada M., Ebara M., Fukuda H., Yoshikawa M., Sugiura N., Saisho H., et al. Clinical evaluation of sonoelasticity measurement in liver using ultrasonic imaging of internal forced low-frequency vibration. Ultrasound Med Biol 26 (2000) 1455-1460
54. Parker K.J., Asztely M.S., Lerner R.M., Schenk E.A., and Waag R.C. In-vivo measurements of ultrasound attenuation in normal or diseased liver. Ultrasound Med Biol 14 (1988) 127-136
55. Cobbold J.F., Morin S., and Taylor-Robinson S.D. Transient elastography for the assessment of chronic liver disease: ready for the clinic?. World J Gastroenterol 13 (2007) 4791-4797
56. Sandrin L., Fourquet B., Hasquenoph J.M., Yon S., Fournier C., Mal F., et al. Transient elastography: A new non-invasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29 (2003) 1705-1713
57. Fraquelli M., Rigamonti C., Conte D., Casazza G., Donato F., Ronchi G., et al. Reproducibility of transient elastography (TE) in assessing hepatic fibrosis. Gut 56 (2007) 968-973
58. Konate A., Boursier J., Reaud S., Quemener E., Fouchard-Hubert I., and Oberti F. Liver stiffness measurement by transient elastography: predictive factors of accuracy, success and reproducibility. J Hepatol 44 (2006) S195
59. Ziol M., Handra-Luca A., Kettaneh A., Christidis C., Mal F., Kazemi F., et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 (2005) 48-54
60. Carrion J.A., Navasa M., Bosch J., Bruguera M., Gilabert R., and Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 12 (2006) 1791-1798
61. Foucher J., Chanteloup E., Vergniol J., Castera L., Le Bail B., Adhoute X., et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55 (2006) 403-408
62. Nguyen-Khac E. Results and place of fibroscan in the non-invasive diagnosis of hepatic fibrosis. Rev Med Interne 28 (2007) 94-102
63. Coco B., Olivieri P., Colombatto P., Ciccorossi P., Sacco R., Bonino F., et al. Liver stiffness measured by transient elastography: the influence of biochemical activity. J Hepatol 44 (2006) S196
64. Ganne-Carrie N., Ziol M., de Ledinghen V., Douvin C., Marcellin P., Castera L., et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 44 (2006) 1511-1517
65. Coco B., Oliveri F., Maina A.M., Ciccorossi P., Sacco R., Colombatto P., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 14 (2007) 360-369
66. Le Tallec V., Le Bigot J., Gorea G., Reaud S., Boursier J., Konate A., et al. Combination of blood scores, doppler ultrasonography, and transient elastography for the diagnosis of liver fibrosis. Hepatology 44 (2006) 453A
67. Friedrich-Rust M., Ong M.F., Herrmann E., Dries V., Samaras P., Zeuzem S., et al. Real-time elastography for non-invasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 188 (2007) 758-764
68. Fraquelli M., and Rigamonti C. Diagnosis of cirrhosis by transient elastography: what is hidden behind misleading results. Hepatology 46 (2007) 282
69. Hotta N., Ayada M., Okumura A., Ishikawa T., Sato K., Oohashi T., et al. Non-invasive assessment of liver disease - measurement of hepatic fibrosis using tissue strain imaging. Clin Imaging 31 (2007) 87-92
70. Bercoff J., Pernot M., Tanter M., and Fink M. Monitoring thermally-induced lesions with supersonic shear imaging. Ultrasound Imaging 26 (2004) 71-84
71. Bercoff J., Tanter M., and Fink M. Supersonic shear imaging: a new technique for soft tissue elasticity mapping. IEEE Trans Ultrasound Ferroelectr Freq Control 51 (2004) 396-409
72. Bercoff J., Tanter M., Muller M., and Fink M. The role of viscosity in the impulse diffraction field of elastic waves induced by the acoustic radiation force. IEEE Trans Ultrasound Ferroelectr Freq Control 51 (2004) 1523-1536
73. Talwalkar J.A., Yin M., Fidler J.L., Sanderson S.O., Kamath P.S., and Ehman R.L. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 47 (2008) 332-342
74. Vogl T., Steiner S., Hahn D., Schedel H., and Lissner J. Diffuse liver parenchymal diseases: the value of MRI compared to sonography and CT. Rofo 154 (1991) 495-503
75. Dodd III G.D., Baron R.L., Oliver Jr. J.H., and Federle M.P. Spectrum of imaging findings of the liver in end-stage cirrhosis: part I, gross morphology and diffuse abnormalities. AJR Am J Roentgenol 173 (1999) 1031-1036
76. Dodd III G.D., Baron R.L., Oliver Jr. J.H., and Federle M.P. Spectrum of imaging findings of the liver in end-stage cirrhosis: Part II, focal abnormalities. AJR Am J Roentgenol 173 (1999) 1185-1192
77. Chappell K.E., Patel N., Gatehouse P.D., Main J., Puri B.K., Taylor-Robinson S.D., et al. Magnetic resonance imaging of the liver with ultrashort TE (UTE) pulse sequences. J Magn Reson Imaging 18 (2003) 709-713
78. Low R.N. Contrast agents for MR imaging of the liver. J Magn Reson Imaging 7 (1997) 56-67
79. Macdonald G.A., and Peduto A.J. Magnetic resonance imaging (MRI) and diseases of the liver and biliary tract part 1. basic principles, MRI in the assessment of diffuse and focal hepatic disease. J Gastroenterol Hepatol 15 (2000) 980-991
80. Aguirre D.A., Behling C.A., Alpert E., Hassanein T.I., and Sirlin C.B. Liver fibrosis: Non-invasive diagnosis with double contrast material-enhanced MR imaging. Radiology 239 (2006) 425-437
81. Hamer O.W., Schlottmann K., Sirlin C.B., and Feuerbach S. Technology insight: advances in liver imaging. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 215-228
82. Lee V.S., Lavelle M.T., Rofsky N.M., Laub G., Thomasson D.M., Krinsky G.A., et al. Hepatic MR imaging with a dynamic contrast-enhanced isotropic volumetric interpolated breath-hold examination: Feasibility, reproducibility, and technical quality. Radiology 215 (2000) 365-372
83. Materne R., Smith A.M., Peeters F., Dehoux J.P., Keyeux A., Horsmans Y., et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 47 (2002) 135-142
84. Kubo H., Harada M., Ishikawa M., and Nishitani H. Hemodynamic changes with liver fibrosis measured by dynamic contrast-enhanced MRI in the rat. Magn Reson Med Sci 5 (2006) 65-71
85. Semelka R.C., Chung J.J., Hussain S.M., Marcos H.B., and Woosley J.T. Chronic hepatitis: Correlation of early patchy and late linear enhancement patterns on gadolinium-enhanced MR images with histopathology initial experience. J Magn Reson Imaging 13 (2001) 385-391
86. Fujita T., Ito K., Honjo K., Okazaki H., Matsumoto T., and Matsunaga N. Hepatic parenchymal enhancement in the cirrhotic liver: evaluation by triple-phase dynamic MRI. Abdom Imaging 27 (2002) 29-33
87. Ryeom H.K., Kim S.H., Kim J.Y., Kim H.J., Lee J.M., Chang Y.M., et al. Quantitative evaluation of liver function with MRI using gd-EOB-DTPA. Korean J Radiol 5 (2004) 231-239
88. Lucidarme O., Baleston F., Cadi M., Bellin M.F., Charlotte F., Ratziu V., et al. Non-invasive detection of liver fibrosis: is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique?. Eur Radiol 13 (2003) 467-474
89. Elizondo G., Weissleder R., Stark D.D., Guerra J., Garza J., Fretz C.J., et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 174 (1990) 797-801
90. Annet L., Materne R., Danse E., Jamart J., Horsmans Y., and Van Beers B.E. Hepatic flow parameters measured with MR imaging and doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 229 (2003) 409-414
91. Hagiwara M., Rusinek H., Lee V.S., Losada M., Bannan M.A., Krinsky G.A., et al. Advanced liver fibrosis: Diagnosis with 3D whole-liver perfusion MR imaging - initial experience. Radiology 246 (2008) 926-934
92. Van Beers B.E., Materne R., Annet L., Hermoye L., Sempoux C., Peeters F., et al. Capillarization of the sinusoids in liver fibrosis: non-invasive assessment with contrast-enhanced MRI in the rabbit. Magn Reson Med 49 (2003) 692-699
93. Kim T., Murakami T., Takahashi S., Hori M., Tsuda K., and Nakamura H. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 173 (1999) 393-398
94. Ichikawa T., Haradome H., Hachiya J., Nitatori T., and Araki T. Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. AJR Am J Roentgenol 170 (1998) 397-402
95. Ichikawa T., Haradome H., Hachiya J., Nitatori T., and Araki T. Diffusion-weighted MR imaging with single-shot echo-planar imaging in the upper abdomen: Preliminary clinical experience in 61 patients. Abdom Imaging 24 (1999) 456-461
96. Moteki T., Horikoshi H., Oya N., Aoki J., and Endo K. Evaluation of hepatic lesions and hepatic parenchyma using diffusion-weighted reordered turboFLASH magnetic resonance images. J Magn Reson Imaging 15 (2002) 564-572
97. Muller M.F., Prasad P., Siewert B., Nissenbaum M.A., Raptopoulos V., and Edelman R.R. Abdominal diffusion mapping with use of a whole-body echo-planar system. Radiology 190 (1994) 475-478
98. Murtz P., Flacke S., Traber F., van den Brink J.S., Gieseke J., and Schild H.H. Abdomen: Diffusion-weighted MR imaging with pulse-triggered single-shot sequences. Radiology 224 (2002) 258-264
99. Butts K., Riederer S.J., Ehman R.L., Felmlee J.P., and Grimm R.C. Echo-planar imaging of the liver with a standard MR imaging system. Radiology 189 (1993) 259-264
100. Taouli B., Vilgrain V., Dumont E., Daire J.L., Fan B., and Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226 (2003) 71-78
101. Taouli B., Martin A.J., Qayyum A., Merriman R.B., Vigneron D., Yeh B.M., et al. Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol 183 (2004) 677-680
102. Guan S., Zhou K.R., Zhao W.D., Peng W.J., Tang F., and Mao J. Magnetic resonance diffusion-weighted imaging in the diagnosis of diffuse liver diseases in rats. Chin Med J (Engl) 118 (2005) 639-644
103. Lewin M., Poujol-Robert A., Boelle P.Y., Wendum D., Lasnier E., Viallon M., et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46 (2007) 658-665
104. Aube C., Racineux P.X., Lebigot J., Oberti F., Croquet V., Argaud C., et al. Diagnosis and quantification of hepatic fibrosis with diffusion weighted MR imaging: preliminary results. J Radiol 85 (2004) 301-306
105. Annet L., Peeters F., Abarca-Quinones J., Leclercq I., Moulin P., and Van Beers B.E. Assessment of diffusion-weighted MR imaging in liver fibrosis. J Magn Reson Imaging 25 (2007) 122-128
106. Girometti R., Furlan A., Bazzocchi M., Soldano F., Isola M., Toniutto P., et al. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med (Torino) 112 (2007) 394-408
107. Koinuma M., Ohashi I., Hanafusa K., and Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 22 (2005) 80-85
108. Boulanger Y., Amara M., Lepanto L., Beaudoin G., Nguyen B.N., Allaire G., et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients. NMR Biomed 16 (2003) 132-136
109. Muthupillai R., Lomas D.J., Rossman P.J., Greenleaf J.F., Manduca A., and Ehman R.L. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 269 (1995) 1854-1857
110. Muthupillai R., Rossman P.J., Lomas D.J., Greenleaf J.F., Riederer S.J., and Ehman R.L. Magnetic resonance imaging of transverse acoustic strain waves. Magn Reson Med 36 (1996) 266-274
111. Rouviere O., Yin M., Dresner M.A., Rossman P.J., Burgart L.J., Fidler J.L., et al. MR elastography of the liver: preliminary results. Radiology 240 (2006) 440-448
112. Yin M., Woollard J., Wang X., Torres V.E., Harris P.C., Ward C.J., et al. Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastography. Magn Reson Med 58 (2007) 346-353
113. Manduca A., Oliphant T.E., Dresner M.A., Mahowald J.L., Kruse S.A., Amromin E., et al. Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal 5 (2001) 237-254
114. Huwart L., Peeters F., Sinkus R., Annet L., Salameh N., ter Beek L.C., et al. Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed 19 (2006) 173-179
115. Huwart L., Sempoux C., Salameh N., Jamart J., Annet L., Sinkus R., et al. Liver fibrosis: non-invasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 245 (2007) 458-466
116. Yin M., Talwalkar J.A., Glaser K.J., Manduca A., Grimm R.C., Rossman P.J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 5 (2007) 1207-1213
117. Klatt D., Asbach P., Rump J., Papazoglou S., Somasundaram R., Modrow J., et al. In vivo determination of hepatic stiffness using steady-state free precession magnetic resonance elastography. Invest Radiol 41 (2006) 841-848
118. Rump J., Klatt D., Braun J., Warmuth C., and Sack I. Fractional encoding of harmonic motions in MR elastography. Magn Reson Med 57 (2007) 388-395
119. Sijens P.E., and Oudkerk M. Clinical magnetic resonance spectroscopy. Imaging Decisions MRI 9 (2005) 23-38
120. Keevil S.F., Alstead E.M., Dolke G., Brooks A.P., Armstrong P., and Farthing M.J. Non-invasive assessment of diffuse liver disease by in vivo measurement of proton nuclear magnetic resonance relaxation times at 008 T. Br J Radiol 67 (1994) 1083-1087
121. Thomsen C., Becker U., Winkler K., Christoffersen P., Jensen M., and Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 12 (1994) 487-495
122. Jalan R., Taylor-Robinson S.D., and Hodgson H.J. In vivo hepatic magnetic resonance spectroscopy: clinical or research tool?. J Hepatol 25 (1996) 414-424
123. Szczepaniak L.S., Babcock E.E., Schick F., Dobbins R.L., Garg A., Burns D.K., et al. Measurement of intracellular triglyceride stores by H spectroscopy: Validation in vivo. Am J Physiol 276 (1999) E977-E989
124. Cho S.G., Kim M.Y., Kim H.J., Kim Y.S., Choi W., Shin S.H., et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 221 (2001) 740-746
125. Tarasow E., Siergiejczyk L., Panasiuk A., Kubas B., Dzienis W., Prokopowicz D., et al. MR proton spectroscopy in liver examinations of healthy individuals in vivo. Med Sci Monit 8 (2002) MT36-MT40
126. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005) E462-E468
127. Thomas E.L., Hamilton G., Patel N., O'Dwyer R., Dore C.J., Goldin R.D., et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54 (2005) 122-127
128. Noren B., Lundberg P., Ressner M., Wirell S., Almer S., and Smedby O. Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease. Eur Radiol 15 (2005) 148-157
129. Noren B., Dahlqvist O., Lundberg P., Almer S., Kechagias S., Ekstedt M., et al. Separation of advanced from mild fibrosis in diffuse liver disease using (31)P magnetic resonance spectroscopy. Eur J Radiol 66 (2008) 313-320
130. van Wassenaer-van Hall H.N., van der Grond J., van Hattum J., Kooijman C., Hoogenraad T.U., and Mali W.P. 31P magnetic resonance spectroscopy of the liver: correlation with standardized serum, clinical, and histological changes in diffuse liver disease. Hepatology 21 (1995) 443-449
131. Jalan R., Sargentoni J., Coutts G.A., Bell J.D., Rolles K., Burroughs A.K., et al. Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. Gut 39 (1996) 141-146
132. Lim A.K., Patel N., Hamilton G., Hajnal J.V., Goldin R.D., and Taylor-Robinson S.D. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 37 (2003) 788-794
133. Meyerhoff D.J., Boska M.D., Thomas A.M., and Weiner M.W. Alcoholic liver disease: quantitative image-guided P-31 MR spectroscopy. Radiology 173 (1989) 393-400
134. Angus P.W., Dixon R.M., Rajagopalan B., Ryley N.G., Simpson K.J., Peters T.J., et al. A study of patients with alcoholic liver disease by 31P nuclear magnetic resonance spectroscopy. Clin Sci (Lond) 78 (1990) 33-38
135. Oberhaensli R.D., Galloway G.J., Taylor D.J., Bore P.J., and Radda G.K. Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. Br J Radiol 59 (1986) 695-699
136. Oberhaensli R., Rajagopalan B., Galloway G.J., Taylor D.J., and Radda G.K. Study of human liver disease with P-31 magnetic resonance spectroscopy. Gut 31 (1990) 463-467
137. Fritz G.A., Schoellnast H., Deutschmann H.A., Wiltgen M., Brader P., Berghold A., et al. Density histogram analysis of unenhanced hepatic computed tomography in patients with diffuse liver diseases. J Comput Assist Tomogr 30 (2006) 201-205
138. Blomley M.J., Coulden R., Dawson P., Kormano M., Donlan P., Bufkin C., et al. Liver perfusion studied with ultrafast CT. J Comput Assist Tomogr 19 (1995) 424-433
139. Quiroga S., Sebastia C., Pallisa E., Castella E., Perez-Lafuente M., and Alvarez-Castells A. Improved diagnosis of hepatic perfusion disorders: value of hepatic arterial phase imaging during helical CT. Radiographics 21 (2001) 65-81
140. Colagrande S., Centi N., Galdiero R., and Ragozzino A. Transient hepatic intensity differences: Part 1, those associated with focal lesions. AJR Am J Roentgenol 188 (2007) 154-159
141. Colagrande S., Centi N., Galdiero R., and Ragozzino A. Transient hepatic intensity differences: part 2, those not associated with focal lesions. AJR Am J Roentgenol 188 (2007) 160-166
142. Partanen K.P. Dynamic CT of liver cirrhosis. Invest Radiol 19 (1984) 303-308
143. Itai Y., Hachiya J., Makita K., Ohtomo K., Kokubo T., and Yamauchi T. Transient hepatic attenuation differences on dynamic computed tomography. J Comput Assist Tomogr 11 (1987) 461-465
144. Chen W.P., Chen J.H., Hwang J.I., Tsai J.W., Chen J.S., Hung S.W., et al. Spectrum of transient hepatic attenuation differences in biphasic helical CT. AJR Am J Roentgenol 172 (1999) 419-424
145. Miles K.A., Hayball M.P., and Dixon A.K. Functional images of hepatic perfusion obtained with dynamic CT. Radiology 188 (1993) 405-411
146. Tsushima Y., Blomley J.K., Kusano S., and Endo K. The portal component of hepatic perfusion measured by dynamic CT: an indicator of hepatic parenchymal damage. Dig Dis Sci 44 (1999) 1632-1638
147. Tsushima Y., Blomley M.J., Kusano S., and Endo K. Measuring portal venous perfusion with contrast-enhanced CT: comparison of direct and indirect methods. Acad Radiol 9 (2002) 276-282
148. Koseoglu K., Taskin F., Ozsunar Y., Cildag B., and Karaman C. Transient hepatic attenuation differences at biphasic spiral CT examinations. Diagn Interv Radiol 11 (2005) 96-101
149. Hashimoto K., Murakami T., Dono K., Hori M., Kim T., Kudo M., et al. Assessment of the severity of liver disease and fibrotic change: the usefulness of hepatic CT perfusion imaging. Oncol Rep 16 (2006) 677-683
150. Van Beers B.E., Leconte I., Materne R., Smith A.M., Jamart J., and Horsmans Y. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. AJR Am J Roentgenol 176 (2001) 667-673
151. Halavaara J.T., Hamberg L.M., Leong F.S., Hunter G.J., Gazelle G.S., and Wolf G.L. Functional CT with an experimental intravascular contrast agent in the assessment of liver vascular physiology. Acad Radiol 3 (1996) 946-952
152. Kapanen M., Halavaara J., and Hakkinen A.M. Comparison of liver perfusion parameters studied with conventional extravascular and experimental intravascular CT contrast agents. Acad Radiol 14 (2007) 951-958
153. Oguro A., Taniguchi H., Koyama H., Tanaka H., Miyata K., Takeuchi K., et al. Relationship between liver function and splenic blood flow (quantitative measurement of splenic blood flow with H2(15)O and a dynamic state method: 2). Ann Nucl Med 7 (1993) 251-255
154. Taniguchi H., Oguro A., Takeuchi K., Miyata K., Takahashi T., Inaba T., et al. Difference in regional hepatic blood flow in liver segments - non-invasive measurement of regional hepatic arterial and portal blood flow in human by positron emission tomography with H2(15)O. Ann Nucl Med 7 (1993) 141-145
155. Taniguchi H., Oguro A., Koyama H., Masuyama M., and Takahashi T. Analysis of models for quantification of arterial and portal blood flow in the human liver using PET. J Comput Assist Tomogr 20 (1996) 135-144
156. Kodama T., Watanabe K., Hoshi H., Jinnouchi S., Arakawa K., Kusumoto S., et al. Diagnosis of diffuse hepatocellular diseases using SPECT. J Nucl Med 27 (1986) 616-619
157. Alstead E.M., Grime J.S., Critchley M., Morris A.I., Gilmore I.T., and Ware J. Is SPECT of the spleen worthwhile in the evaluation of liver disease severity?. Nucl Med Commun 8 (1987) 33-43
158. Virgolini I., Muller C., Angelberger P., Hobart J., Bergmann H., and Sinzinger H. Quantification of human hepatic binding protein (HBP) via 99mTc-galactosyl-neoglycoalbumin (NGA) liver scintigraphy. Wien Klin Wochenschr 103 (1991) 458-461
159. Delcourt E., Vanhaeverbeek M., Binon J.P., Brasseur P., Calay R., Baudoux M., et al. Emission tomography for assessment of diffuse alcoholic liver disease. J Nucl Med 33 (1992) 1337-1344
160. Kudo M., Todo A., Ikekubo K., Yamamoto K., Vera D.R., and Stadalnik R.C. Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99 m galactosyl human serum albumin. Hepatology 17 (1993) 814-819
161. Ono K., Kato H., Nishibe T., Tanabe T., Nagao K., and Ito K. Clinical evaluation of hepatic blood flow and liver function with 99mTc-DTPA-HSA. Nippon Geka Gakkai Zasshi 94 (1993) 816-823
162. Pimstone N.R., Stadalnik R.C., Vera D.R., Hutak D.P., and Trudeau W.L. Evaluation of hepatocellular function by way of receptor-mediated uptake of a technetium-99m-labeled asialoglycoprotein analog. Hepatology 20 (1994) 917-923
163. Wu J., Ishikawa N., Takeda T., Tanaka Y., Pan X.Q., Sato M., et al. The functional hepatic volume assessed by 99mTc-GSA hepatic scintigraphy. Ann Nucl Med 9 (1995) 229-235
164. Vera D.R., Stadalnik R.C., Metz C.E., and Pimstone N.R. Diagnostic performance of a receptor-binding radiopharmacokinetic model. J Nucl Med 37 (1996) 160-164
165. Ha-Kawa S.K., Tanaka Y., Hasebe S., Kuniyasu Y., Koizumi K., Ishii Y., et al. Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: A multicentre study. Eur J Nucl Med 24 (1997) 130-137
166. Matsuzaki S., Onda M., Tajiri T., and Kim D.Y. Hepatic lobar differences in progression of chronic liver disease: correlation of asialoglycoprotein scintigraphy and hepatic functional reserve. Hepatology 25 (1997) 828-832
167. Ichihara T., Maeda H., Yamakado K., Motomura N., Matsumura K., Takeda K., et al. Quantitative analysis of scatter- and attenuation-compensated dynamic single-photon emission tomography for functional hepatic imaging with a receptor-binding radiopharmaceutical. Eur J Nucl Med 24 (1997) 59-67
168. Kwon A.H., Ha-Kawa S.K., Uetsuji S., Inoue T., Matsui Y., and Kamiyama Y. Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy. Hepatology 25 (1997) 426-429
169. Tanaka A., Shinohara H., Hatano E., Sato S., Kanazawa A., Yamaoka Y., et al. Perioperative changes in hepatic function as assessed by asialoglycoprotein receptor indices by technetium 99m galactosyl human serum albumin. Hepatogastroenterol 46 (1999) 369-375
170. Kwon A.H., Matsui Y., Ha-Kawa S.K., and Kamiyama Y. Functional hepatic volume measured by technetium-99m-galactosyl-human serum albumin liver scintigraphy: Comparison between hepatocyte volume and liver volume by computed tomography. Am J Gastroenterol 96 (2001) 541-546
171. Kinoshita K., Ukikusa M., Iwaisako K., Arimoto A., Fujisawa N., Ozaki T., et al. Preoperative assessment of hepatic function: utility of a new convenient two-compartment model analysis using galactosyl human serum albumin scintigraphy. J Gastroenterol Hepatol 18 (2003) 99-104
172. Onodera Y., Takahashi K., Togashi T., Sugai Y., Tamaki N., and Miyasaka K. Clinical assessment of hepatic functional reserve using 99mTc DTPA galactosyl human serum albumin SPECT to prognosticate chronic hepatic diseases-validation of the use of SPECT and a new indicator. Ann Nucl Med 17 (2003) 181-188
173. Shiramizu B., Theodore D., Bassett R., Coel M., Sherman K.E., Glesby M.J., et al. Correlation of single photon emission computed tomography parameters as a non-invasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the adult AIDS clinical trials group. J Acquir Immune Defic Syndr 33 (2003) 329-335
174. Zuckerman E., Slobodin G., Sabo E., Yeshurun D., Naschitz J.E., and Groshar D. Quantitative liver-spleen scan using single photon emission computerized tomography (SPECT) for assessment of hepatic function in cirrhotic patients. J Hepatol 39 (2003) 326-332
175. Poynard T., Halfon P., Castera L., Munteanu M., Imbert-Bismut F., Ratziu V., et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 53 (2007) 1615-1622
176. Aube C., Winkfield B., Oberti F., Vuillemin E., Rousselet M.C., Caron C., et al. New doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. Eur J Gastroenterol Hepatol 16 (2004) 743-751
177. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 24 (1996) 289-293
178. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
179. Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 105 (1993) 274-278
180. Dinc H., Sari A., Resit Gumele H., Cihanyurdu N., and Baki A. Portal and splanchnic haemodynamics in patients with advanced post-hepatitic cirrhosis and in healthy adults. Assessment with duplex doppler ultrasound. Acta Radiol 39 (1998) 152-156
181. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
182. Hirata M., Akbar S.M., Horiike N., and Onji M. Non-invasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. Eur J Clin Invest 31 (2001) 528-535
183. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., and Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
184. Iwao T., Toyonaga A., Oho K., Tayama C., Masumoto H., Sakai T., et al. Value of doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension. Am J Gastroenterol 92 (1997) 1012-1017
185. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
186. Lim A.K., Patel N., Eckersley R.J., Kuo Y.T., Goldin R.D., Thomas H.C., et al. Can doppler sonography grade the severity of hepatitis C-related liver disease?. AJR Am J Roentgenol 184 (2005) 1848-1853
187. Liu C.H., Lin J.W., Tsai F.C., Yang P.M., Lai M.Y., Chen J.H., et al. Non-invasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 26 (2006) 1087-1094
188. Piscaglia F., Gaiani S., Calderoni D., Donati G., Celli N., Gramantieri L., et al. Influence of liver fibrosis on hepatic artery doppler resistance index in chronic hepatitis of viral origin. Scand J Gastroenterol 36 (2001) 647-652
189. Zironi G., Gaiani S., Fenyves D., Rigamonti A., Bolondi L., and Barbara L. Value of measurement of mean portal flow velocity by doppler flowmetry in the diagnosis of portal hypertension. J Hepatol 16 (1992) 298-303
190. Giuseppetti G.M., Argalia G., and Abbattista T. Liver cirrhosis: Evaluation of haemodynamic changes using an ultrasound contrast agent. Eur J Radiol 51 (2004) 27-33
191. Pedersen J.F., Larsen V.A., Bytzer P., Madsen L.G., and Hamberg O. Hepatic transit time of ultrasound contrast in biopsy characterized liver disease. Acta Radiol 46 (2005) 557-560
192. Ridolfi F., Abbattista T., Marini F., Vedovelli A., Quagliarini P., Busilacchi P., et al. Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C. Dig Liver Dis 39 (2007) 929-935
193. Mettler F.A., Huda W., Yoshizumi T.T., and Mahesh M. A catalog of effective doses in radiology and nuclear medicine. Radiology 248 (2008) 254-263
194. RADAR medical procedure radiation dose calculator [homepage on the Internet]. 2007. Available from: .